טוען...
Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience
BACKGROUND: Infliximab (IFX) infusion may lead to development of anti-IFX antibodies, and subsequent infusion reactions (IRs). The safety of rapid IFX infusion administered over 60 minutes has been under-investigated in children with inflammatory bowel disease. In a multicenter study, the frequency...
שמור ב:
| הוצא לאור ב: | Inflamm Bowel Dis |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551232/ https://ncbi.nlm.nih.gov/pubmed/29140940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MIB.0000000000001259 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|